Reporting and Interpretation of the CYP2C19 Genotyping Test for Clopidogrel Dosing

E-ISSN： 1875-6913|8|4|268-272

ISSN： 1875-6921

Source： Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol.8, Iss.4, 2010-12, pp. : 268-272

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Beyond CYP2C19 – A New Chapter in Clopidogrel Pharmacogenomics

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 41, Iss. 1, 2011-03 ,pp. : 14-16

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost–effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia

By Sorich Michael J Horowitz John D Sorich Wassana Wiese Michael D Pekarsky Brita Karnon Jonathan D

Pharmacogenomics, Vol. 14, Iss. 16, 2013-12 ,pp. : 2013-2021

Future Medicine

Access to resources Recommend Favorite

Interaction Between Clopidogrel and Proton Pump Inhibitors: Hypothesis to Explain Multifactorial CYP2C19 Inhibition

Drug Metabolism Letters, Vol. 3, Iss. 4, 2009-12 ,pp. : 287-289

Bentham Science Publishers

Access to resources Recommend Favorite

Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry

By Falzoi Matteo Mossa Alessandra Congeddu Elena Saba Luisella Pani Luca

Pharmacogenomics, Vol. 11, Iss. 4, 2010-04 ,pp. : 559-571

Future Medicine

Access to resources Recommend Favorite

Hydroxylation of R (+)- and S (−)-Omeprazole after Racemic Dosing are Different among the CYP2C19 Genotypes

By Shiohira Hideo

Pharmaceutical Research, Vol. 29, Iss. 8, 2012-08 ,pp. : 2310-2316

Springer Publishing Company

Access to resources Recommend Favorite